# US 2013/0095493 A1 · Identification of the gene notch3 as a novel biomarker for human metastatic melanoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0095493 A1
- Document ID: US20130095493A1
- Status: Published application
- Kind: A1
- Application number: 13/644,131
- Filed: 2012-10-03
- Published: 2013-04-18
- Earliest claimed: 2011-10-03
- Assignees: The Johns Hopkins University
- Inventors: Rhoda Myra Alani; Jason David Howard
- Web page: https://patentgrep.com/patent/US20130095493A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- G01N 33/5751: of the skin, e.g. melanoma
- G01N 2500/10: involving cells
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/54: Determining the risk of relapse
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides evidence that Notch3 gene upregulation is associated with invasive metastatic melanoma. Assays for quantifying Notch3 expression in biological samples and methods of use for diagnosis, and assaying progression and treatment outcome using these assays are also provided. Methods of screening for compounds which inhibit Notch3 expression are also provided.

## Claims

### Claim 1

A method for detecting or diagnosing melanoma in a subject comprising:
(a) obtaining a biological sample from the subject;
(b) detecting the presence of i) cells expressing Notch3, ii) soluble Notch3, or iii) a soluble fragment of Notch3 in the sample; and
(c) correlating the expression of Notch3 with the presence of melanoma, thereby detecting or diagnosing melanoma in a subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is taken from the skin, blood, serum or tumor.

### Claim 3 (depends on 2)

The method of claim 2, further comprising comparing the level of expression of Notch3 in the subject to the level of expression in one or more control samples, and when the level of expression of Notch3 is higher in the subject than the control levels, an indication of the presence of melanoma is made.

### Claim 4 (depends on 3)

The method of claim 3, wherein the detection of Notch3 expression is made by the use of monoclonal antibodies to Notch3 having a detectable label.

### Claim 5 (depends on 3)

The method of claim 3, wherein the detection of Notch3 expression is made by the use of an ELISA assay.

### Claim 6

A method of predicting recurrence of melanoma in a subject comprising:
(a) obtaining a biological sample from the subject;
(b) detecting the presence of i) cells expressing Notch3, ii) soluble Notch3, or iii) a soluble fragment of Notch3 in the sample; and
(c) correlating the expression of Notch3 with the presence of melanoma, thereby predicting the recurrence of melanoma in a subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein the biological sample is taken from the skin, blood, serum or tumor.

### Claim 8 (depends on 7)

The method of claim 7, further comprising comparing the level of expression of Notch3 in the subject to the level of expression in one or more control samples, and when the level of expression of Notch3 is higher in the subject than the control levels, an indication of the presence of melanoma is made.

### Claim 9 (depends on 8)

The method of claim 8, wherein the detection of Notch3 expression is made by the use of monoclonal antibodies to Notch3 having a detectable label.

### Claim 10 (depends on 8)

The method of claim 8, wherein the detection of Notch3 expression is made by the use of an ELISA assay.

### Claim 11

A method of identifying a subject at risk of developing melanoma comprising:
(a) obtaining a biological sample from the subject;
(b) detecting the presence of i) cells expressing Notch3, ii) soluble Notch3, or iii) a soluble fragment of Notch3 in the sample; and
(c) correlating the expression of Notch3 with the presence of melanoma, thereby identifying a subject at risk of developing melanoma.

### Claim 12 (depends on 11)

The method of claim 11, wherein the biological sample is taken from the skin, blood, serum or tumor.

### Claim 13 (depends on 12)

The method of claim 12, further comprising comparing the level of expression of Notch3 in the subject to the level of expression in one or more control samples, and when the level of expression of Notch3 is higher in the subject than the control levels, an indication of the presence of melanoma is made.

### Claim 14 (depends on 13)

The method of claim 13, wherein the detection of Notch3 expression is made by the use of monoclonal antibodies to Notch3 having a detectable label.

### Claim 15 (depends on 13)

The method of claim 13, wherein the detection of Notch3 expression is made by the use of an ELISA assay.

### Claim 16

A method for screening one or more Notch3 activity inhibitor candidates comprising:
1) constructing a transformant by transfecting a host cell with a plasmid comprising a polynucleotide encoding Notch3;
2) treating the transformant with a control substance, and treating the transformant with one or more Notch3 activity inhibitor candidates (experimental group);
3) measuring Notch3 activities in the experimental group and in the control group of step 2); and
4) selecting Notch3 activity inhibitor candidates that demonstrate an inhibitory effect when compared with the control group.

### Claim 17 (depends on 16)

The method for screening one or more Notch3 activity inhibitor candidates according to claim 16, wherein the one or more candidates are selected from the group consisting of natural compounds, synthetic compounds, RNA, DNA, polypeptides, enzymes, proteins, ligands, antibodies, antigens, bacterial or fungal metabolites and biological molecules.
